ALEC
Alector, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-33/100
Last price
1.79
▼ 0.20 (10.05%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.07
Prev close
1.99
Day high
2.23
Day low
1.75
Volume
10.15M
Market cap
$202.10M
P/E (TTM)
—
52W range
1.09 – 3.40
Day trading desk
Gap from prior close
+4.01%
Prior close 1.99
VWAP
1.96
-8.90% from price
Relative volume
3.53×
Unusually busy
Session range
27.38%
1.75 – 2.23
Position in range
8%
Near session low
ATR (14D)
0.20
11.17% of price
Prior day high
2.73
PDH
Prior day low
1.96
PDL
Bid / ask spread
—
Quote not published
Session volume
9.18M
Avg 2.60M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.21%
-5.2%
1M
-26.42%
-27.6%
3M
-1.09%
-5.6%
6M
-26.72%
-44.9%
YTD
+16.03%
+1.8%
1Y
-45.48%
-61.9%
3Y
-72.07%
-154.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on ALEC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+1.05M
Net buying
Buy transactions
10
1.28M shares
Sell transactions
7
228.88K shares
Net transactions
+17
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
10.62M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 4, 26 | WONG-SARAD GRACE Officer |
SELL | 9.45K | $24.67K | Direct |
| Sep 3, 26 | BERKLEY NEIL LINDSAY Chief Financial Officer |
SELL | 29.25K | $77.95K | Direct |
| Sep 3, 26 | ROSENTHAL ARNON Chief Executive Officer |
SELL | 72.61K | $193.47K | Direct |
| Aug 19, 26 | ROSENTHAL ARNON Chief Executive Officer |
STOCK | 1.05M | $0 | Indirect |
| Jul 9, 26 | WONG-SARAD GRACE Officer |
STOCK | 20.00K | $0 | Direct |
| Jun 17, 26 | SCHELLER RICHARD H Director |
STOCK | 28.70K | $0 | Direct |
| Jun 17, 26 | ALTMEYER MARK Director |
STOCK | 28.70K | $0 | Direct |
| Jun 17, 26 | YAFFE KRISTINE Director |
STOCK | 28.70K | $0 | Direct |
| Jun 17, 26 | HAMMOND PAULA Director |
STOCK | 28.70K | $0 | Direct |
| Jun 17, 26 | GAROFALO ELIZABETH AMY M.D. Director |
STOCK | 28.70K | $0 | Direct |
| Jun 17, 26 | LAVIGNE LOUIS J JR Director |
STOCK | 28.70K | $0 | Direct |
| Jun 17, 26 | DESOUZA ERROL B Director |
STOCK | 28.70K | $0 | Direct |
| Jun 3, 26 | WONG-SARAD GRACE Officer |
SELL | 9.18K | $17.81K | Direct |
| Jun 2, 26 | BERKLEY NEIL LINDSAY Chief Financial Officer |
SELL | 19.36K | $38.22K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BERKLEY NEIL LINDSAY |
Chief Financial Officer | 350.65K | Sale |
GAROFALO ELIZABETH AMY M.D. |
Director | 118.65K | Stock Award(Grant) |
GRASSO MARC |
Chief Financial Officer | 296.07K | Sale |
KENKARE-MITRA SARASWATI |
President | 501.65K | Sale |
LAVIGNE LOUIS J JR |
Director | 138.66K | Stock Award(Grant) |
ROMANO GARY |
Officer | 332.98K | Sale |
ROSENTHAL ARNON |
Chief Executive Officer | 6.22M | Sale |
SCHELLER RICHARD H |
Director | 134.90K | Stock Award(Grant) |
WONG-SARAD GRACE |
Officer | 106.02K | Sale |
YAFFE KRISTINE |
Director | 124.11K | Stock Award(Grant) |
Fundamentals
Market cap$202.10M
Enterprise value$62.06M
Revenue (TTM)$13.86M
Gross profit$-85.27M
EBITDA$-119.03M
Net income$-117.85M
EPS (TTM)$-1.09
Free cash flow$-107.25M
Total cash$172.80M
Total debt$32.76M
Book value / share$-0.09
Shares outstanding111.66M
Float84.94M
Short % of float5.79%
Dividend yield0.00%
Beta (5Y)0.62
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.52
PEG ratio—
Price / sales—
Price / book—
EV / revenue4.48
EV / EBITDA-0.52
Gross margin0.00%
Operating margin-734.73%
Profit margin0.00%
Return on equity-385.11%
Return on assets-27.62%
Debt / equity—
Current ratio5.26
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $21.05M | $100.56M | $97.06M | $133.62M | -79.1% |
| Operating revenue | $21.05M | $100.56M | $97.06M | $133.62M | -79.1% |
| Research & development | $123.06M | $185.94M | $192.12M | $210.42M | -33.8% |
| Selling, general & admin | $53.99M | $59.62M | $56.69M | $61.03M | -9.4% |
| Total operating expense | $177.05M | $245.56M | $248.80M | $271.45M | -27.9% |
| Operating income | -$156.01M | -$145.00M | -$151.74M | -$137.83M | -7.6% |
| Pre-tax income | -$142.76M | -$118.92M | -$125.18M | -$130.06M | -20.0% |
| Tax provision | $168.00K | $128.00K | $5.21M | $3.25M | +31.3% |
| Net income | -$142.93M | -$119.05M | -$130.39M | -$133.31M | -20.1% |
| Net income to common | -$142.93M | -$119.05M | -$130.39M | -$133.31M | -20.1% |
| Basic EPS | -1.39 | -1.23 | -1.56 | -1.62 | -13.0% |
| Diluted EPS | -1.39 | -1.23 | -1.56 | -1.62 | -13.0% |
| EBIT | -$156.01M | -$145.00M | -$151.74M | -$137.83M | -7.6% |
| EBITDA | -$146.35M | -$136.16M | -$142.89M | -$129.36M | -7.5% |
| Basic shares | 103.00M | 96.59M | 83.73M | 82.47M | +6.6% |
| Diluted shares | 103.00M | 96.59M | 83.73M | 82.47M | +6.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $65.80M | $33.02M | $74.56M | $154.32M | +99.3% |
| Cash & short-term investments | $256.02M | $413.40M | $548.86M | $712.85M | -38.1% |
| Total current assets | $266.45M | $424.82M | $565.81M | $726.43M | -37.3% |
| Property, plant & equipment | $24.55M | $37.10M | $47.06M | $53.33M | -33.8% |
| Total assets | $293.24M | $468.30M | $621.83M | $787.65M | -37.4% |
| Total current liabilities | $69.50M | $125.06M | $177.95M | $93.81M | -44.4% |
| Current debt | $366.00K | — | — | — | — |
| Long-term debt | $9.32M | $9.39M | — | — | -0.7% |
| Total debt | $36.23M | $42.52M | $38.92M | $43.33M | -14.8% |
| Total liabilities | $262.59M | $341.50M | $487.67M | $573.21M | -23.1% |
| Retained earnings | -$972.06M | -$829.13M | -$710.08M | -$579.69M | -17.2% |
| Shareholder equity | $30.65M | $126.80M | $134.16M | $214.44M | -75.8% |
| Working capital | $196.95M | $299.76M | $387.86M | $632.63M | -34.3% |
| Net tangible assets | $30.65M | $126.80M | $134.16M | $214.44M | -75.8% |
| Shares issued | 110.36M | 99.09M | 84.88M | 82.90M | +11.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$142.93M | -$119.05M | -$130.39M | -$133.31M | -20.1% |
| Depreciation & amortisation | $9.66M | $8.84M | $8.85M | $8.47M | +9.3% |
| Stock-based compensation | $26.66M | $39.46M | $42.80M | $46.15M | -32.4% |
| Change in working capital | -$74.06M | -$146.99M | -$90.15M | $59.53M | +49.6% |
| Operating cash flow | -$184.03M | -$229.91M | -$184.16M | -$20.33M | +20.0% |
| Capital expenditure | -$41.00K | -$1.25M | -$2.38M | -$4.12M | +96.7% |
| Investing cash flow | $196.60M | $107.13M | $101.92M | -$159.01M | +83.5% |
| Financing cash flow | $20.21M | $81.54M | $2.55M | $4.51M | -75.2% |
| Free cash flow | -$184.07M | -$231.16M | -$186.54M | -$24.45M | +20.4% |
| End cash position | $67.65M | $34.87M | $76.10M | $155.79M | +94.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.32M | $1.05M | $6.24M | $3.26M | $7.87M | +217.4% |
| Operating revenue | $3.32M | $1.05M | $6.24M | $3.26M | $7.87M | +217.4% |
| Research & development | $19.46M | $17.86M | $32.46M | $29.35M | $27.61M | +9.0% |
| Selling, general & admin | $8.25M | $8.11M | $13.34M | $11.52M | $14.40M | +1.8% |
| Total operating expense | $27.71M | $25.96M | $45.80M | $40.87M | $42.01M | +6.7% |
| Operating income | -$24.39M | -$24.92M | -$39.57M | -$37.61M | -$34.14M | +2.1% |
| Pre-tax income | -$22.86M | -$22.93M | -$37.10M | -$34.67M | -$30.52M | +0.3% |
| Tax provision | $130.00K | $0 | $168.00K | $0 | $0 | — |
| Net income | -$22.99M | -$22.93M | -$37.27M | -$34.67M | -$30.52M | -0.3% |
| Net income to common | -$22.99M | -$22.93M | -$37.27M | -$34.67M | -$30.52M | -0.3% |
| Basic EPS | -0.21 | -0.21 | -0.34 | -0.34 | -0.30 | 0.0% |
| Diluted EPS | -0.21 | -0.21 | -0.34 | -0.34 | -0.30 | 0.0% |
| EBIT | -$24.39M | -$24.92M | -$39.57M | -$37.61M | -$34.14M | +2.1% |
| EBITDA | -$22.34M | -$22.84M | -$37.31M | -$35.28M | -$30.92M | +2.2% |
| Basic shares | 111.22M | 110.59M | 109.52M | 102.60M | 100.37M | +0.6% |
| Diluted shares | 111.22M | 110.59M | 109.52M | 102.60M | 100.37M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $59.91M | $76.96M | $65.80M | $76.50M | $44.77M | — | -22.1% |
| Cash & short-term investments | $172.80M | $206.51M | $256.02M | $291.11M | $307.28M | — | -16.3% |
| Total current assets | $180.09M | $215.08M | $266.45M | $300.38M | $319.18M | — | -16.3% |
| Property, plant & equipment | $20.57M | $22.62M | $24.55M | $28.58M | $30.90M | — | -9.1% |
| Total assets | $202.85M | $239.92M | $293.24M | $335.29M | $356.42M | — | -15.4% |
| Total current liabilities | $34.24M | $40.97M | $69.50M | $79.96M | $84.35M | — | -16.4% |
| Current debt | $9.85M | $1.48M | $366.00K | — | — | — | +565.4% |
| Long-term debt | — | $8.29M | $9.32M | $9.61M | $9.54M | $9.46M | — |
| Total debt | $32.76M | $34.55M | $36.23M | $37.88M | $39.48M | — | -5.2% |
| Total liabilities | $212.82M | $229.53M | $262.59M | $277.57M | $285.25M | — | -7.3% |
| Retained earnings | -$1.02B | -$994.99M | -$972.06M | -$934.79M | -$900.12M | — | -2.3% |
| Shareholder equity | -$9.97M | $10.38M | $30.65M | $57.71M | $71.17M | — | -196.0% |
| Working capital | $145.85M | $174.12M | $196.95M | $220.42M | $234.82M | — | -16.2% |
| Net tangible assets | -$9.97M | $10.38M | $30.65M | $57.71M | $71.17M | — | -196.0% |
| Shares issued | 111.66M | 111.03M | 110.36M | 107.45M | 101.21M | — | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$22.99M | -$22.93M | -$37.27M | -$34.67M | -$30.52M | — | -0.3% |
| Depreciation & amortisation | $2.05M | $2.08M | $2.26M | $2.33M | $3.22M | — | -1.7% |
| Stock-based compensation | $2.61M | $2.91M | $4.84M | $6.40M | $7.06M | — | -10.2% |
| Change in working capital | -$15.46M | -$31.29M | -$12.13M | -$5.11M | -$28.27M | — | +50.6% |
| Operating cash flow | -$34.22M | -$49.81M | -$41.69M | -$32.51M | -$49.05M | — | +31.3% |
| Capital expenditure | -$31.00K | -$118.00K | — | -$11.00K | -$10.00K | -$20.00K | +73.7% |
| Investing cash flow | $17.12M | $60.95M | $25.60M | $49.54M | $55.72M | — | -71.9% |
| Financing cash flow | $50.00K | $25.00K | $5.39M | $14.70M | $122.00K | — | +100.0% |
| Free cash flow | -$34.25M | -$49.93M | -$41.69M | -$32.52M | -$49.06M | — | +31.4% |
| End cash position | $61.76M | $78.81M | $67.65M | $78.35M | $46.62M | — | -21.6% |
Options analytics
Put / call volume
0.15
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
0.50
-72.4% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
+25.0%
Puts bid over calls
Call volume
1.30K
Contracts, this expiry
Put volume
192
Contracts, this expiry
Heaviest call OI
7.50
91 contracts
Heaviest put OI
0.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.23 | -0.21 | +8.0% |
| Mar 2026 | -0.28 | -0.21 | +24.2% |
| Dec 2025 | -0.36 | -0.34 | +6.4% |
| Sep 2025 | -0.41 | -0.34 | +17.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.21 | 6 | $2.85M | -12.5% |
| Next quarter | -0.09 | 6 | $3.75M | -39.8% |
| Current year | -0.69 | 6 | $27.09M | +28.7% |
| Next year | -0.73 | 6 | $33.80M | +24.8% |
Analyst targets & ownership
Mean target$3.30
High target$6.00
Low target$1.00
Implied upside84.36%
Analyst count5
ConsensusHOLD
Strong buy / Buy0 / 3
Hold2
Sell / Strong sell1 / 1
Held by insiders9.52%
Held by institutions93.29%
Institutions holding190
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.90
-5.79% from price
SMA 20
1.97
-8.17% from price
SMA 50
2.03
-10.97% from price
SMA 100
1.92
-6.58% from price
SMA 200
2.00
-9.39% from price
EMA 12
1.92
-6.73% from price
EMA 26
1.99
-10.16% from price
EMA 50
2.00
-10.56% from price
RSI (14)
41.7
Neutral
MACD (12,26,9)
-0.07
Hist -0.02
ATR (14)
0.20
11.05% of price
Realised vol 30D
80.8%
Annualised
Bollinger upper
2.23
20, 2σ
Bollinger lower
1.71
20, 2σ
50 / 200 cross
Golden
2.03 vs 2.00
Trend bias
Below 200
-9.39%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.71
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
80.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-65.6%
Peak to trough
Max drawdown 5Y
-96.5%
Peak to trough
ATR 14
0.20
11.05% of price
Beta (reported)
0.62
5Y monthly, from filing
Short interest
Shares short
6.10M
Prior 5.90M
Change vs prior
+3.4%
Shorts adding
% of float
5.79%
Normal
% of shares out
5.47%
Against total outstanding
Days to cover
3.8
Liquid
Float
84.94M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | Morgan Stanley | MAINTAINED | Underweight | Underweight |
| Apr 15, 26 | Cantor Fitzgerald | UPGRADE | Neutral | Overweight |
| Mar 10, 26 | BTIG | UPGRADE | Neutral | Buy |
| Oct 22, 25 | TD Cowen | DOWNGRADE | Buy | Hold |
| Oct 22, 25 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| Oct 22, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 22, 25 | William Blair | DOWNGRADE | Outperform | Market Perform |
| Oct 22, 25 | BTIG | DOWNGRADE | Buy | Neutral |
| Sep 25, 25 | BTIG | MAINTAINED | Buy | Buy |
| Jul 28, 25 | Mizuho | UPGRADE | Neutral | Outperform |
| May 9, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 27, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-08
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-05-07
Annual Report to Shareholders
ARS · 2026-04-28
Offering Registrations
S-3 · 2026-03-12
Offering Registrations
S-8 · 2026-02-25
Headlines
Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal
GuruFocus.com · 10h ago
Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
Pharmaceutical Technology · 18h ago
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · 1d ago
Sector Update: Healthcare
MT Newswires · 1d ago
Update: Alector Shares Rise After Licensing AL050 Program to Roche's Genentech
MT Newswires · 1d ago
BC-Most Active Stocks
Associated Press · 2d ago
Alector Signs $1.27 Billion Genentech License Agreement for Parkinson’s Disease Program
InvestorsHub · 2d ago
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
BioPharma Dive · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.